Trial Profile
An Intergroup Randomized Phase II Study of Bevacizumab (NSC 704865) or Cetuximab (NSC 714692) in Combination With Gemcitabine and in Combination With Chemoradiation (Capecitabine and Radiation) in Patients With Completely-Resected Pancreatic Carcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cetuximab (Primary) ; Capecitabine; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions
- 20 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jun 2010 Results have been presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).
- 11 Jan 2008 Status changed from recruiting to in progress.